This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision
2026-03-13 10:56:52 ET
Deerfield Management Company disclosed a buy of 418,538 shares of Vera Therapeutics (NASDAQ:VERA) in its February 17, 2026, SEC filing, with an estimated transaction value of $14.87 million based on the quarter’s average price.
According to a recent SEC filing , Deerfield Management Company increased its holding in Vera Therapeutics (NASDAQ:VERA) by 418,538 shares during the fourth quarter of 2025. The estimated transaction value, calculated using the period’s average closing price, was approximately $14.87 million. The quarter-end value of the stake increased by $99.77 million, reflecting both the additional shares purchased and changes in the stock price during the period.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Brisbane, California. The company differentiates itself through the development of innovative biologic therapies targeting unmet needs in immunological diseases, leveraging advanced protein and antibody platforms. With a robust pipeline and focus on high-burden indications, Vera Therapeutics is positioned to address significant gaps in current treatment options for rare and serious conditions.
NASDAQ: VERA
VERA Trading
0.55% G/L:
$40.04 Last:
312,334 Volume:
$40.57 Open:
